Combining targeted drug with chemotherapy offers longer life to b-cell cancer patients

Related posts:

1. Targeted agent pacritinib significantly reduces burden of advanced myelofibrosis in patients Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent....
2. Practice-changing study offers new option for tough breast cancer cases A new phase 3 study in some of the most difficult-to-treat patients, women with endocrine-resistant disease, showed that the newly approved drug, palbociclib, more than doubled the time to cancer recurrence for women with hormone-receptor (HR+) positive metastatic breast cancer....
3. Human Hendra drug, treatment not prevention In a world first in the battle against the deadly Hendra virus, volunteers are being recruited to trial a human treatment for the virus....
4. Anticoagulant medications: Newer, easier to manage medications may not always be the best choice If you are over age 75, and taking an anticoagulant, the old standard may be the gold standard, Mayo Clinic researchers and collaborators have determined....
5. Impulsivity linked to binge eating Do you get impulsive when you're upset? If so, this could be putting you at risk for binge eating. The more impulsive you are, the more likely it is you'll binge eat when experiencing negative feelings....